The Prospective Segeberg TAVI Registry

NCT03192774 · tracked via the Priya Life Science Germany tracker

Sponsor

Segeberger Kliniken GmbH

Phase

Observational

Started

2007-09

Last updated

2022-06-06

Condition(s) studied

Aortic Valve Stenosis

Investigational drug(s) / intervention(s)

Transcatheter Aortic Valve Implantation

Transcatheter Aortic Valve Implantation: Interventional replacement of the aortic valve

Study summary

A single center registry including all patients treated with TAVI at the Heart Center, Bad Segeberg, Germany

Eligibility

Sex

ALL

Min age

18 Years

Max age

100 Years

Healthy volunteers

Inclusion Criteria: * All patients treated with TAVI Exclusion Criteria: * None

Primary outcome measure(s)

Mortality — Up to 10 years
Cardiovascular and not cardiovascular death

Trial sites (1)

Facility	City	Region	Status
Heart Center, Segeberger Kliniken	Bad Segeberg	Germany	Recruiting

More Segeberger Kliniken GmbH trials in Germany

The Prospective Segeberg Registry for Rotational Atherectomy in Coronary Lesion/s Recruiting

The Prospective Segeberg Registry for Coronary Chronic Total Occlusions (CTO) Recruiting

The Prospective Segeberg Registry for Mitral Transcatheter Edge-to-Edge Repair Recruiting

Other trials for the same condition

accuRate Evaluation of Benefit With Optimal Medical Treatment With or Without Transcatheter Valve Repair of PARADOXical Low Flow Low Gradient Aortic Stenosis Active, not recruiting

Correlation of FFR and iFR With Cardiac PET Perfusion in Patients With Severe Aortic Valve Stenosis Recruiting

Effect of Fetal Aortic Valvuloplasty on Outcomes Recruiting

Randomized Trial of TAVI vs. SAVR in Patients With Severe Aortic Valve Stenosis at Low to Intermediate Risk of Mortality Active, not recruiting

Balloon- Versus Self-Expanding Intraannular TAVI in Small Aortic Annuli Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03192774 on ClinicalTrials.gov ↗ ← All trials in Germany